An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register

Femke H. M. Prince, Esther W. de Bekker-Grob, Marinka Twilt, Marion A. J. van Rossum, Esther P. A. H. Hoppenreijs, Rebecca ten Cate, Yvonne Koopman-Keemink, Simone L. Gorter, Hein Raat, Lisette W. A. van Suijlekom-Smit

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1131-1136
JournalRheumatology
Volume50
Issue number6
DOIs
Publication statusPublished - Jun 2011

Keywords

  • Juvenile idiopathic arthritis
  • Paediatric rheumatology
  • National register study
  • Etanercept
  • Tumour necrosis factor-alpha
  • Biologic
  • Treatment costs
  • Cost-effectiveness
  • Cost-utility
  • Health utilities index

Cite this

Prince, F. H. M., de Bekker-Grob, E. W., Twilt, M., van Rossum, M. A. J., Hoppenreijs, E. P. A. H., ten Cate, R., Koopman-Keemink, Y., Gorter, S. L., Raat, H., & van Suijlekom-Smit, L. W. A. (2011). An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology, 50(6), 1131-1136. https://doi.org/10.1093/rheumatology/keq432